Find Clinical Trial

Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study comparing S 18886 30 mg o.d. versus aspirin 100 mg o.d. administered orally.


← Back
Study Phase

Phase 2

Therapeutic Area

Metabolism

IndicationDiabetes - Type II
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

TERUTROBAN,
S018886

Active Substance CodeS018886
Protocol CodeCL2-18886-031
EudraCT Code2008-005262-31


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility